{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:59:35Z","timestamp":1792652375863,"version":"4.5.0"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T00:00:00Z","timestamp":1655164800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T00:00:00Z","timestamp":1655164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1038\/s41386-022-01360-y","type":"journal-article","created":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T08:05:05Z","timestamp":1655193905000},"page":"1608-1619","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Symptomatic and neurotrophic effects of GABAA receptor positive allosteric modulation in a mouse model of chronic stress"],"prefix":"10.1038","volume":"47","author":[{"given":"Ashley","family":"Bernardo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Marcotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Yeunus","family":"Mian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sepideh","family":"Rezvanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dishary","family":"Sharmin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Kova\u010devi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miroslav M.","family":"Savi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5832-6570","authenticated-orcid":false,"given":"Etienne","family":"Sibille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6774-603X","authenticated-orcid":false,"given":"Thomas D.","family":"Prevot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,14]]},"reference":[{"key":"1360_CR1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/pcn.12463","volume":"71","author":"GM MacQueen","year":"2017","unstructured":"MacQueen GM, Memedovich KA. Cognitive dysfunction in major depression and bipolar disorder: Assessment and treatment options. Psychiatry Clin Neurosci. 2017;71:18\u201327.","journal-title":"Psychiatry Clin Neurosci"},{"key":"1360_CR2","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1016\/S0140-6736(18)31948-2","volume":"392","author":"GS Malhi","year":"2018","unstructured":"Malhi GS, Mann JJ. Depression. Lancet. 2018;392:2299\u2013312.","journal-title":"Lancet"},{"key":"1360_CR3","doi-asserted-by":"publisher","first-page":"e014912","DOI":"10.1136\/bmjopen-2016-014912","volume":"7","author":"G Gartlehner","year":"2017","unstructured":"Gartlehner G, et al. Pharmacological and non-pharmacological treatments for major depressive disorder: review of systematic reviews. BMJ Open. 2017;7:e014912.","journal-title":"BMJ Open"},{"issue":"Suppl 6","key":"1360_CR4","first-page":"4","volume":"61","author":"RMA Hirschfeld","year":"2000","unstructured":"Hirschfeld RMA. History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry. 2000;61(Suppl 6):4\u20136.","journal-title":"J Clin Psychiatry"},{"key":"1360_CR5","doi-asserted-by":"publisher","first-page":"107875","DOI":"10.1016\/j.pharmthera.2021.107875","volume":"226","author":"C-Y Xia","year":"2021","unstructured":"Xia C-Y, et al. Targeting the dysfunction of glutamate receptors for the development of novel antidepressants. Pharmacol Therapeutics. 2021;226:107875.","journal-title":"Pharmacol Therapeutics"},{"key":"1360_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01327-5","volume":"11","author":"MT Davis","year":"2021","unstructured":"Davis MT, et al. Acute cognitive effects of single-dose intravenous ketamine in major depressive and posttraumatic stress disorder. Transl Psychiatry. 2021;11:205.","journal-title":"Transl Psychiatry"},{"key":"1360_CR7","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.neubiorev.2020.11.020","volume":"120","author":"H Gill","year":"2021","unstructured":"Gill H, et al. The effects of ketamine on cognition in treatment-resistant depression: A systematic review and priority avenues for future research. Neurosci Biobehav Rev. 2021;120:78\u201385.","journal-title":"Neurosci Biobehav Rev"},{"key":"1360_CR8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41380-020-0727-3","volume":"26","author":"T Prevot","year":"2021","unstructured":"Prevot T, Sibille E. Altered GABA-mediated information processing and cognitive dysfunctions in depression and other brain disorders. Mol Psychiatry. 2021;26:151\u201367.","journal-title":"Mol Psychiatry"},{"key":"1360_CR9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.neulet.2015.01.022","volume":"601","author":"CH Duman","year":"2015","unstructured":"Duman CH, Duman RS. Spine synapse remodeling in the pathophysiology and treatment of depression. Neurosci Lett. 2015;601:20\u20139.","journal-title":"Neurosci Lett"},{"key":"1360_CR10","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S2215-0366(15)00579-9","volume":"3","author":"LM Williams","year":"2016","unstructured":"Williams LM. Precision psychiatry: A neural circuit taxonomy for depression and anxiety. Lancet Psychiatry. 2016;3:472\u201380.","journal-title":"Lancet Psychiatry."},{"key":"1360_CR11","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.ceb.2011.09.002","volume":"23","author":"M Banasr","year":"2011","unstructured":"Banasr M, Dwyer JM, Duman RS. Cell atrophy and loss in depression: Reversal by antidepressant treatment. Curr Opin Cell Biol. 2011;23:730\u20137.","journal-title":"Curr Opin Cell Biol"},{"key":"1360_CR12","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1038\/nm.2886","volume":"18","author":"HJ Kang","year":"2012","unstructured":"Kang HJ, et al. Decreased expression of synapse-related genes and loss of synapses in major depressive disorder. Nat Med. 2012;18:1413\u20137.","journal-title":"Nat Med"},{"key":"1360_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09562-7","volume":"10","author":"SE Holmes","year":"2019","unstructured":"Holmes SE, et al. Lower synaptic density is associated with depression severity and network alterations. Nat Commun. 2019;10:1529.","journal-title":"Nat Commun"},{"key":"1360_CR14","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1038\/s41386-018-0093-x","volume":"43","author":"JI Lissemore","year":"2018","unstructured":"Lissemore JI, et al. Reduced GABAergic cortical inhibition in aging and depression. Neuropsychopharmacology. 2018;43:2277\u201384.","journal-title":"Neuropsychopharmacology"},{"key":"1360_CR15","doi-asserted-by":"publisher","first-page":"5846","DOI":"10.2174\/138161212803523644","volume":"18","author":"JC Lee","year":"2012","unstructured":"Lee JC, et al. The role of transcranial magnetic stimulation in treatment-resistant depression: A review. Curr Pharm Des. 2012;18:5846\u201352.","journal-title":"Curr Pharm Des"},{"key":"1360_CR16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3389\/fncel.2019.00087","volume":"13","author":"MV Fogaca","year":"2019","unstructured":"Fogaca MV, Duman RS. Cortical GABAergic dysfunction in stress and depression: New insights for therapeutic interventions. Front Cell Neurosci. 2019;13:87.","journal-title":"Front Cell Neurosci"},{"key":"1360_CR17","doi-asserted-by":"crossref","unstructured":"Newton, DF, et al. Chapter 28 - Altered GABAergic Function, Cortical Microcircuitry, and Information Processing in Depression, in Neurobiology of Depression, J Quevedo, AF Carvalho, and CA Zarate, Editors. 2019, Academic Press. p. 315\u201329.","DOI":"10.1016\/B978-0-12-813333-0.00028-7"},{"key":"1360_CR18","first-page":"255","volume":"11","author":"Z Bhagwagar","year":"2008","unstructured":"Bhagwagar Z, et al. Low GABA concentrations in occipital cortex and anterior cingulate cortex in medication-free, recovered depressed patients. Int J Neuropsychopharmacol\/Off Sci J Collegium Int Neuropsychopharmacologicum (CINP). 2008;11:255\u201360.","journal-title":"Int J Neuropsychopharmacol\/Off Sci J Collegium Int Neuropsychopharmacologicum (CINP)"},{"key":"1360_CR19","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1001\/archpsyc.58.6.556","volume":"58","author":"AW Goddard","year":"2001","unstructured":"Goddard AW, et al. Reductions in occipital Cortex GABA levels in panic disorder detected with 1H-Magnetic resonance spectroscopy. Arch Gen Psychiatry. 2001;58:556\u2013556.","journal-title":"Arch Gen Psychiatry"},{"key":"1360_CR20","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.biopsych.2008.10.025","volume":"65","author":"RB Price","year":"2009","unstructured":"Price RB, et al. Amino acid neurotransmitters assessed by proton magnetic resonance spectroscopy: Relationship to treatment resistance in major depressive disorder. Biol Psychiatry. 2009;65:792\u2013800.","journal-title":"Biol Psychiatry"},{"key":"1360_CR21","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1001\/archpsyc.61.7.705","volume":"61","author":"G Sanacora","year":"2004","unstructured":"Sanacora G, et al. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry. 2004;61:705\u201313.","journal-title":"Arch Gen Psychiatry"},{"key":"1360_CR22","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1176\/appi.ajp.159.4.663","volume":"159","author":"G Sanacora","year":"2002","unstructured":"Sanacora G, et al. Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am J Psychiatry. 2002;159:663\u20135.","journal-title":"Am J Psychiatry"},{"key":"1360_CR23","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1001\/archpsyc.61.7.705","volume":"61","author":"G Sanacora","year":"2004","unstructured":"Sanacora G, et al. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry. 2004;61:705\u201313.","journal-title":"Arch Gen Psychiatry"},{"key":"1360_CR24","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1001\/archpsyc.56.11.1043","volume":"56","author":"G Sanacora","year":"1999","unstructured":"Sanacora G, et al. Reduced cortical \u03b3-Aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 1999;56:1043\u20131043.","journal-title":"Arch Gen Psychiatry"},{"key":"1360_CR25","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1001\/archpsyc.64.2.193","volume":"64","author":"G Hasler","year":"2007","unstructured":"Hasler G, et al. Reduced prefrontal glutamate\/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 2007;64:193\u2013200.","journal-title":"Arch Gen Psychiatry"},{"key":"1360_CR26","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1001\/archgenpsychiatry.2011.131","volume":"69","author":"V Gabbay","year":"2012","unstructured":"Gabbay V, et al. Anterior cingulate Cortex\u03b3-Aminobutyric acid in depressed adolescents. Arch Gen Psychiatry. 2012;69:139\u2013139.","journal-title":"Arch Gen Psychiatry"},{"key":"1360_CR27","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1038\/npp.2012.4","volume":"37","author":"DT Plante","year":"2012","unstructured":"Plante DT, et al. Reduced gamma-aminobutyric acid in occipital and anterior cingulate cortices in primary insomnia: A link to major depressive disorder? Neuropsychopharmacology. 2012;37:1548\u201357.","journal-title":"Neuropsychopharmacology"},{"key":"1360_CR28","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.pnpbp.2008.10.005","volume":"33","author":"AM Feyissa","year":"2009","unstructured":"Feyissa AM, et al. Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Prog Neuro-Psychopharmacol Biol Psychiatry. 2009;33:70\u201375.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"1360_CR29","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1515\/RNS.2011.044","volume":"22","author":"DJ Christoffel","year":"2011","unstructured":"Christoffel DJ, Golden SA, Russo SJ. Structural and synaptic plasticity in stress-related disorders. Rev Neurosci. 2011;22:535\u201349.","journal-title":"Rev Neurosci"},{"key":"1360_CR30","doi-asserted-by":"publisher","first-page":"5733","DOI":"10.1523\/JNEUROSCI.0474-06.2006","volume":"26","author":"A Izquierdo","year":"2006","unstructured":"Izquierdo A, Wellman CL, Holmes A. Brief uncontrollable stress causes dendritic retraction in infralimbic cortex and resistance to fear extinction in mice. J Neurosci. 2006;26:5733\u20138.","journal-title":"J Neurosci"},{"key":"1360_CR31","doi-asserted-by":"publisher","first-page":"7870","DOI":"10.1523\/JNEUROSCI.1184-06.2006","volume":"26","author":"C Liston","year":"2006","unstructured":"Liston C, et al. Stress-induced alterations in prefrontal cortical dendritic morphology predict selective impairments in perceptual attentional set-shifting. J Neurosci. 2006;26:7870\u20134.","journal-title":"J Neurosci"},{"key":"1360_CR32","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1093\/cercor\/bhp003","volume":"19","author":"RM Shansky","year":"2009","unstructured":"Shansky RM, et al. Stress-induced dendritic remodeling in the prefrontal cortex is circuit specific. Cereb Cortex. 2009;19:2479\u201384.","journal-title":"Cereb Cortex"},{"key":"1360_CR33","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.euroneuro.2015.04.025","volume":"25","author":"CG Abdallah","year":"2015","unstructured":"Abdallah CG, et al. Prefrontal cortical GABA abnormalities are associated with reduced hippocampal volume in major depressive disorder. Eur Neuropsychopharmacol. 2015;25:1082\u201390.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1360_CR34","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/mp.2008.119","volume":"14","author":"JM Bessa","year":"2009","unstructured":"Bessa JM, et al. The mood-improving actions of antidepressants do not depend on neurogenesis but are associated with neuronal remodeling. Mol Psychiatry. 2009;14:764\u201373.","journal-title":"Mol Psychiatry"},{"key":"1360_CR35","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.neuroscience.2010.04.035","volume":"169","author":"E Ampuero","year":"2010","unstructured":"Ampuero E, et al. Chronic fluoxetine treatment induces structural plasticity and selective changes in glutamate receptor subunits in the rat cerebral cortex. Neuroscience. 2010;169:98\u2013108.","journal-title":"Neuroscience"},{"key":"1360_CR36","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.brainres.2015.04.058","volume":"1616","author":"K Lyttle","year":"2015","unstructured":"Lyttle K, et al. Repeated fluvoxamine treatment recovers juvenile stress-induced morphological changes and depressive-like behavior in rats. Brain Res. 2015;1616:88\u2013100.","journal-title":"Brain Res"},{"key":"1360_CR37","doi-asserted-by":"crossref","unstructured":"Phoumthipphavong, V, et al., Longitudinal effects of ketamine on dendritic architecture in vivo in the mouse medial frontal cortex. eNeuro, 2016. 3: p. ENEURO.0133-15.2016.","DOI":"10.1523\/ENEURO.0133-15.2016"},{"key":"1360_CR38","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1172\/JCI130808","volume":"130","author":"DM Gerhard","year":"2020","unstructured":"Gerhard DM, et al. GABA interneurons are the cellular trigger for ketamine\u2019s rapid antidepressant actions. J Clin Invest. 2020;130:1336\u201349.","journal-title":"J Clin Invest"},{"key":"1360_CR39","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00441-006-0284-3","volume":"326","author":"H Mohler","year":"2006","unstructured":"Mohler H. GABA(A) receptor diversity and pharmacology. Cell Tissue Res. 2006;326:505\u201316.","journal-title":"Cell Tissue Res"},{"key":"1360_CR40","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.tips.2018.03.006","volume":"39","author":"E Sigel","year":"2018","unstructured":"Sigel E, Ernst M. The Benzodiazepine binding sites of GABAA receptors. Trends Pharmacol Sci. 2018;39:659\u201371.","journal-title":"Trends Pharmacol Sci"},{"key":"1360_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40263-015-0305-4","volume":"30","author":"A Pariente","year":"2016","unstructured":"Pariente A, et al. The Benzodiazepine\u2013dementia disorders link: Current state of knowledge. CNS Drugs. 2016;30:1\u20137.","journal-title":"CNS Drugs"},{"key":"1360_CR42","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1124\/pr.117.014449","volume":"70","author":"W Sieghart","year":"2018","unstructured":"Sieghart W, Savi\u0107 MM. International Union of basic and clinical pharmacology. CVI: GABA(A) Receptor subtype- and function-selective ligands: Key issues in translation to humans. Pharm Rev. 2018;70:836\u201378.","journal-title":"Pharm Rev"},{"key":"1360_CR43","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/cne.903590111","volume":"359","author":"JM Fritschy","year":"1995","unstructured":"Fritschy JM, Mohler H. GABAA-receptor heterogeneity in the adult rat brain: differential regional and cellular distribution of seven major subunits. J Comp Neurol. 1995;359:154\u201394.","journal-title":"J Comp Neurol"},{"key":"1360_CR44","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3389\/fncir.2012.00032","volume":"6","author":"R Geracitano","year":"2012","unstructured":"Geracitano R, et al. Functional expression of the GABA(A) receptor \u03b12 and \u03b13 subunits at synapses between intercalated medial paracapsular neurons of mouse amygdala. Front Neural Circuits. 2012;6:32.","journal-title":"Front Neural Circuits"},{"key":"1360_CR45","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1002\/cne.24337","volume":"526","author":"H Stefanits","year":"2018","unstructured":"Stefanits H, et al. GABAA receptor subunits in the human amygdala and hippocampus: Immunohistochemical distribution of 7 subunits. J Comp Neurol. 2018;526:324\u201348.","journal-title":"J Comp Neurol"},{"key":"1360_CR46","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1111\/j.1460-9568.2004.03574.x","volume":"20","author":"A Marowsky","year":"2004","unstructured":"Marowsky A, Fritschy JM, Vogt KE. Functional mapping of GABA A receptor subtypes in the amygdala. Eur J Neurosci. 2004;20:1281\u20139.","journal-title":"Eur J Neurosci"},{"key":"1360_CR47","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1111\/j.1460-9568.2007.05970.x","volume":"26","author":"SA Heldt","year":"2007","unstructured":"Heldt SA, Ressler KJ. Training-induced changes in the expression of GABAA-associated genes in the amygdala after the acquisition and extinction of Pavlovian fear. Eur J Neurosci. 2007;26:3631\u201344.","journal-title":"Eur J Neurosci"},{"key":"1360_CR48","doi-asserted-by":"publisher","first-page":"10682","DOI":"10.1523\/JNEUROSCI.1166-05.2005","volume":"25","author":"R Dias","year":"2005","unstructured":"Dias R, et al. Evidence for a significant role of alpha 3-containing GABAA receptors in mediating the anxiolytic effects of benzodiazepines. J Neurosci. 2005;25:10682\u20138.","journal-title":"J Neurosci"},{"key":"1360_CR49","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neuropharm.2011.08.040","volume":"62","author":"H M\u00f6hler","year":"2012","unstructured":"M\u00f6hler H. The GABA system in anxiety and depression and its therapeutic potential. Neuropharmacology. 2012;62:42\u201353.","journal-title":"Neuropharmacology"},{"key":"1360_CR50","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/7854_2009_30","volume":"2","author":"JR Atack","year":"2010","unstructured":"Atack JR. GABAA receptor alpha2\/alpha3 subtype-selective modulators as potential nonsedating anxiolytics. Curr Top Behav Neurosci. 2010;2:331\u201360.","journal-title":"Curr Top Behav Neurosci"},{"key":"1360_CR51","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.pharmthera.2012.08.006","volume":"136","author":"E Engin","year":"2012","unstructured":"Engin E, Liu J, Rudolph U. \u03b12-containing GABA(A) receptors: a target for the development of novel treatment strategies for CNS disorders. Pharmacol therapeutics. 2012;136:142\u201352.","journal-title":"Pharmacol therapeutics"},{"key":"1360_CR52","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1021\/jm0110789","volume":"45","author":"I Collins","year":"2002","unstructured":"Collins I, et al. 3-Heteroaryl-2-pyridones: Benzodiazepine site ligands with functional delectivity for alpha 2\/alpha 3-subtypes of human GABA(A) receptor-ion channels. J Med Chem. 2002;45:1887\u2013900.","journal-title":"J Med Chem"},{"key":"1360_CR53","first-page":"247","volume":"21","author":"BH Miller","year":"2010","unstructured":"Miller BH, et al. Quantitative trait locus analysis identifies Gabra3 as a regulator of behavioral despair in mice. Mammalian genome: official journal of the International Mammalian Genome. Society. 2010;21:247\u201357.","journal-title":"Society"},{"key":"1360_CR54","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.neuropharm.2012.06.023","volume":"64","author":"MT Koh","year":"2013","unstructured":"Koh MT, Rosenzweig-Lipson S, Gallagher M. Selective GABA(A) alpha5 positive allosteric modulators improve cognitive function in aged rats with memory impairment. Neuropharmacology. 2013;64:145\u201352.","journal-title":"Neuropharmacology"},{"key":"1360_CR55","first-page":"84","volume":"5","author":"T Prevot","year":"2019","unstructured":"Prevot T, et al. Novel Benzodiazepine-like ligands with various anxiolytic, antidepressant, or pro-cognitive profiles. Molecular. Mol Neuropsychiatry. 2019;5:84\u201397.","journal-title":"Mol Neuropsychiatry"},{"key":"1360_CR56","first-page":"190","volume":"9","author":"T Sigurdsson","year":"2016","unstructured":"Sigurdsson T, Duvarci S. Hippocampal-prefrontal interactions in cognition. Behav Psychiatr Dis Front Syst Neurosci. 2016;9:190\u2013190.","journal-title":"Behav Psychiatr Dis Front Syst Neurosci"},{"key":"1360_CR57","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.neuropharm.2012.06.023","volume":"64","author":"MT Koh","year":"2013","unstructured":"Koh MT, Rosenzweig-Lipson S, Gallagher M. Selective GABA(A) \u03b15 positive allosteric modulators improve cognitive function in aged rats with memory impairment. Neuropharmacology. 2013;64:145\u201352.","journal-title":"Neuropharmacology"},{"key":"1360_CR58","doi-asserted-by":"crossref","unstructured":"Prevot, TD, et al. Reversal of Age-Related Neuronal Atrophy by \u03b15-GABAA Receptor Positive Allosteric Modulation. Cereb Cortex, 2020;31:1395\u20131408.","DOI":"10.1093\/cercor\/bhaa310"},{"key":"1360_CR59","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/44579","volume":"401","author":"U Rudolph","year":"1999","unstructured":"Rudolph U, et al. Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature. 1999;401:796\u2013800.","journal-title":"Nature"},{"key":"1360_CR60","doi-asserted-by":"publisher","first-page":"158","DOI":"10.24820\/ark.5550190.p010.460","volume":"2018","author":"G Li","year":"2018","unstructured":"Li G, et al. Synthesis of chiral GABA(A) receptor subtype selective ligands as potential agents to treat schizophrenia as well as depression. Arkivoc. 2018;2018:158\u201382.","journal-title":"Arkivoc"},{"key":"1360_CR61","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1111\/epi.16394","volume":"60","author":"S Billakota","year":"2019","unstructured":"Billakota S, et al. Personalized medicine: Vinpocetine to reverse effects of GABRB3 mutation. Epilepsia. 2019;60:2459\u201365.","journal-title":"Epilepsia"},{"key":"1360_CR62","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1089\/adt.2015.688","volume":"14","author":"GE Kirsch","year":"2016","unstructured":"Kirsch GE, et al. Electrophysiology-based assays to detect subtype-selective modulation of human nicotinic acetylcholine receptors. ASSAY Drug Dev Technol. 2016;14:333\u201344.","journal-title":"ASSAY Drug Dev Technol"},{"key":"1360_CR63","first-page":"20","volume":"2","author":"MK Bayliss","year":"1999","unstructured":"Bayliss MK, Frick LW. High-throughput pharmacokinetics: Cassette dosing. Curr Opin Drug Disco Devel. 1999;2:20\u20135.","journal-title":"Curr Opin Drug Disco Devel"},{"key":"1360_CR64","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.ejphar.2016.09.016","volume":"791","author":"TT Stamenic","year":"2016","unstructured":"Stamenic TT, et al. Ester to amide substitution improves selectivity, efficacy and kinetic behavior of a benzodiazepine positive modulator of GABAA receptors containing the alpha5 subunit. Eur J Pharm. 2016;791:433\u201343.","journal-title":"Eur J Pharm"},{"key":"1360_CR65","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.brainres.2014.01.036","volume":"1554","author":"A Obradovic","year":"2014","unstructured":"Obradovic A, et al. Sh-I-048A, an in vitro non-selective super-agonist at the benzodiazepine site of GABAA receptors: The approximated activation of receptor subtypes may explain behavioral effects. Brain Res. 2014;1554:36\u201348.","journal-title":"Brain Res"},{"key":"1360_CR66","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1177\/1087057103255988","volume":"8","author":"L Di","year":"2003","unstructured":"Di L, et al. Optimization of a higher throughput microsomal stability screening assay for profiling drug discovery candidates. J Biomolecular Screen. 2003;8:453\u201362.","journal-title":"J Biomolecular Screen"},{"key":"1360_CR67","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.neuropharm.2019.05.005","volume":"153","author":"TD Prevot","year":"2019","unstructured":"Prevot TD, et al. Residual avoidance: A new, consistent and repeatable readout of chronic stress-induced conflict anxiety reversible by antidepressant treatment. Neuropharmacology. 2019;153:98\u2013110.","journal-title":"Neuropharmacology"},{"key":"1360_CR68","doi-asserted-by":"crossref","unstructured":"Nollet, M, Guisquet AM Le, Belzung C. Models of depression: unpredictable chronic mild stress in mice. Curr Protoc Pharmacol. 2013;5:Unit 5.65.","DOI":"10.1002\/0471141755.ph0565s61"},{"key":"1360_CR69","first-page":"245","volume":"7","author":"P Faucher","year":"2015","unstructured":"Faucher P, et al. Hippocampal injections of Oligomeric Amyloid \u03b2-peptide (1-42) induce selective working memory deficits and long-lasting alterations of ERK signaling pathway. Front Aging Neurosci. 2015;7:245.","journal-title":"Front Aging Neurosci"},{"key":"1360_CR70","doi-asserted-by":"publisher","first-page":"7141","DOI":"10.1073\/pnas.0402147101","volume":"101","author":"CC Wu","year":"2004","unstructured":"Wu CC, et al. Selective vulnerability of dentate granule cells prior to amyloid deposition in PDAPP mice: digital morphometric analyses. Proc Natl Acad Sci USA. 2004;101:7141\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1360_CR71","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jneumeth.2011.01.019","volume":"197","author":"J-P Guilloux","year":"2011","unstructured":"Guilloux J-P, et al. Integrated behavioral z-scoring increases the sensitivity and reliability of behavioral phenotyping in mice: Relevance to emotionality and sex. J Neurosci Methods. 2011;197:21\u201331.","journal-title":"J Neurosci Methods"},{"key":"1360_CR72","first-page":"10","volume":"1","author":"BS Sekhon","year":"2013","unstructured":"Sekhon BS. Exploiting the power of stereochemistry in drugs: An overview of racemic and enantiopure drugs. J Mod Med Chem. 2013;1:10\u201336.","journal-title":"J Mod Med Chem"},{"key":"1360_CR73","doi-asserted-by":"crossref","first-page":"85","DOI":"10.59566\/IJBS.2006.2085","volume":"2","author":"LA Nguyen","year":"2006","unstructured":"Nguyen LA, He H, Pham-Huy C. Chiral drugs: An overview. Int J Biomed Sci: IJBS. 2006;2:85\u2013100.","journal-title":"Int J Biomed Sci: IJBS"},{"key":"1360_CR74","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1002\/jps.1074","volume":"90","author":"NR Srinivas","year":"2001","unstructured":"Srinivas NR, Barbhaiya RH, Midha KK. Enantiomeric drug development: Issues, considerations, and regulatory requirements. J Pharm Sci. 2001;90:1205\u201315.","journal-title":"J Pharm Sci"},{"key":"1360_CR75","doi-asserted-by":"publisher","first-page":"495","DOI":"10.15171\/apb.2017.061","volume":"7","author":"M Bud\u0103u","year":"2017","unstructured":"Bud\u0103u M, et al. Chirality of modern antidepressants: An overview. Adv Pharm Bull. 2017;7:495\u2013500.","journal-title":"Adv Pharm Bull"},{"key":"1360_CR76","doi-asserted-by":"crossref","unstructured":"Zarate, CA, Commentary on the Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder. Canadian J Psychiatry. 2021:66:573\u2013539.","DOI":"10.1177\/07067437211004023"},{"key":"1360_CR77","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1038\/sj.npp.1300749","volume":"30","author":"ME Henry","year":"2005","unstructured":"Henry ME, et al. A comparison of brain and serum pharmacokinetics of R-fluoxetine and racemic fluoxetine: A 19-F MRS study. Neuropsychopharmacology. 2005;30:1576\u201383.","journal-title":"Neuropsychopharmacology"},{"key":"1360_CR78","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1017\/S1092852900028595","volume":"7","author":"JM Gorman","year":"2002","unstructured":"Gorman JM, Korotzer A, Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectr. 2002;7:40\u20134.","journal-title":"CNS Spectr"},{"key":"1360_CR79","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1517\/17460441.2014.907790","volume":"9","author":"L Perez-Caballero","year":"2014","unstructured":"Perez-Caballero L, et al. Fluoxetine: a case history of its discovery and preclinical development. Expert Opin Drug Disco. 2014;9:567\u201378.","journal-title":"Expert Opin Drug Disco"},{"key":"1360_CR80","first-page":"241","volume":"25","author":"K Bezchlibnyk-Butler","year":"2000","unstructured":"Bezchlibnyk-Butler K, Aleksic I, Kennedy SH. Citalopram-a review of pharmacological and clinical effects. J Psychiatry Neurosci. 2000;25:241\u201354.","journal-title":"J Psychiatry Neurosci"},{"key":"1360_CR81","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.jad.2020.09.071","volume":"278","author":"A Bahji","year":"2021","unstructured":"Bahji A, Vazquez GH, Zarate CA Jr. Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. J Affect Disord. 2021;278:542\u201355.","journal-title":"J Affect Disord"},{"key":"1360_CR82","doi-asserted-by":"publisher","first-page":"261","DOI":"10.31887\/DCNS.2002.4.3\/hmoehler","volume":"4","author":"H M\u00f6hler","year":"2002","unstructured":"M\u00f6hler H. Pathophysiological aspects of diversity in neuronal inhibition: A new benzodiazepine pharmacology. Dialogues Clin Neurosci. 2002;4:261\u20139.","journal-title":"Dialogues Clin Neurosci"},{"key":"1360_CR83","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.neuron.2018.09.029","volume":"100","author":"AI Abbas","year":"2018","unstructured":"Abbas AI, et al. Somatostatin interneurons facilitate hippocampal-prefrontal synchrony and prefrontal spatial encoding. Neuron. 2018;100:926\u2013939.","journal-title":"Neuron"},{"key":"1360_CR84","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.neulet.2015.01.022","volume":"601","author":"CH Duman","year":"2015","unstructured":"Duman CH, Duman RS. Spine synapse remodeling in the pathophysiology and treatment of depression. Neurosci Lett. 2015;601:20\u201329.","journal-title":"Neurosci Lett"},{"key":"1360_CR85","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.pnpbp.2018.01.022","volume":"86","author":"TD Pr\u00e9v\u00f4t","year":"2018","unstructured":"Pr\u00e9v\u00f4t TD, et al. sst(2)-receptor gene deletion exacerbates chronic stress-induced deficits: Consequences for emotional and cognitive ageing. Prog Neuropsychopharmacol Biol Psychiatry. 2018;86:390\u2013400.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1360_CR86","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4137\/DTI.S13870","volume":"8","author":"E Gumuslu","year":"2014","unstructured":"Gumuslu E, et al. The antidepressant agomelatine improves memory deterioration and upregulates CREB and BDNF gene expression levels in unpredictable chronic mild stress (UCMS)-exposed mice. Drug Target Insights. 2014;8:11\u201321.","journal-title":"Drug Target Insights"},{"key":"1360_CR87","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.neuroscience.2020.05.034","volume":"440","author":"C Fee","year":"2020","unstructured":"Fee C, et al. Chronic stress-induced behaviors correlate with exacerbated acute stress-induced cingulate cortex and ventral hippocampus activation. Neuroscience. 2020;440:113\u201329.","journal-title":"Neuroscience"},{"key":"1360_CR88","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.neuroscience.2013.01.008","volume":"236","author":"H H\u00f6rtnagl","year":"2013","unstructured":"H\u00f6rtnagl H, et al. Patterns of mRNA and protein expression for 12 GABAA receptor subunits in the mouse brain. Neuroscience. 2013;236:345\u201372.","journal-title":"Neuroscience"},{"key":"1360_CR89","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06004-8","volume":"9","author":"JM Schulz","year":"2018","unstructured":"Schulz JM, et al. Dendrite-targeting interneurons control synaptic NMDA-receptor activation via nonlinear \u03b15-GABA(A) receptors. Nat Commun. 2018;9:3576.","journal-title":"Nat Commun"},{"key":"1360_CR90","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/cne.21115","volume":"499","author":"DR Serwanski","year":"2006","unstructured":"Serwanski DR, et al. Synaptic and nonsynaptic localization of GABAA receptors containing the alpha5 subunit in the rat brain. J Comp Neurol. 2006;499:458\u201370.","journal-title":"J Comp Neurol"},{"key":"1360_CR91","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/j.1460-9568.2011.07782.x","volume":"34","author":"V Duveau","year":"2011","unstructured":"Duveau V, et al. Spatiotemporal specificity of GABAA receptor-mediated regulation of adult hippocampal neurogenesis. Eur J Neurosci. 2011;34:362\u201373.","journal-title":"Eur J Neurosci"},{"key":"1360_CR92","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1111\/ejn.13329","volume":"44","author":"F Deprez","year":"2016","unstructured":"Deprez F, et al. Partial inactivation of GABAA receptors containing the \u03b15 subunit affects the development of adult-born dentate gyrus granule cells. Eur J Neurosci. 2016;44:2258\u201371.","journal-title":"Eur J Neurosci"},{"key":"1360_CR93","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1002\/dneu.22280","volume":"75","author":"ML Brady","year":"2015","unstructured":"Brady ML, Jacob TC. Synaptic localization of \u03b15 GABA (A) receptors via gephyrin interaction regulates dendritic outgrowth and spine maturation. Dev Neurobiol. 2015;75:1241\u201351.","journal-title":"Dev Neurobiol"},{"key":"1360_CR94","doi-asserted-by":"crossref","unstructured":"Moda-Sava RN, et al. Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation. Science. 2019;364;eaat8078.","DOI":"10.1126\/science.aat8078"},{"key":"1360_CR95","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-017-0083-5","volume":"8","author":"YS Nikolova","year":"2018","unstructured":"Nikolova YS, et al. Shifting priorities: highly conserved behavioral and brain network adaptations to chronic stress across species. Transl Psychiatry. 2018;8:26.","journal-title":"Transl Psychiatry"},{"key":"1360_CR96","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3389\/fnins.2018.00367","volume":"12","author":"X Zhang","year":"2018","unstructured":"Zhang X, et al. Stress-Induced Functional Alterations in Amygdala: Implications for Neuropsychiatric Diseases. Front Neurosci. 2018;12:367\u2013367.","journal-title":"Front Neurosci"},{"key":"1360_CR97","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/mp.2010.120","volume":"16","author":"B Luscher","year":"2011","unstructured":"Luscher B, Shen Q, Sahir N. The GABAergic deficit hypothesis of major depressive disorder. Mol Psychiatry. 2011;16:383\u2013406.","journal-title":"Mol Psychiatry"},{"key":"1360_CR98","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1017\/S1461145709990587","volume":"13","author":"B Karolewicz","year":"2010","unstructured":"Karolewicz B, et al. Reduced level of glutamic acid decarboxylase-67 kDa in the prefrontal cortex in major depression. Int J Neuropsychopharmacol. 2010;13:411\u201320.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1360_CR99","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1503\/jpn.160228","volume":"43","author":"B Romeo","year":"2018","unstructured":"Romeo B, et al. Meta-analysis of central and peripheral \u03b3-aminobutyric acid levels in patients with unipolar and bipolar depression. J Psychiatry Neurosci. 2018;43:58\u201366.","journal-title":"J Psychiatry Neurosci"},{"key":"1360_CR100","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1001\/archpsyc.64.2.193","volume":"64","author":"G Hasler","year":"2007","unstructured":"Hasler G, et al. Reduced prefrontal glutamate\/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 2007;64:193\u2013200.","journal-title":"Arch Gen Psychiatry"},{"key":"1360_CR101","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.neubiorev.2018.12.002","volume":"99","author":"S Antoniuk","year":"2019","unstructured":"Antoniuk S, et al. Chronic unpredictable mild stress for modeling depression in rodents: Meta-analysis of model reliability. Neurosci Biobehav Rev. 2019;99:101\u201316.","journal-title":"Neurosci Biobehav Rev"},{"key":"1360_CR102","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.bbr.2006.07.029","volume":"175","author":"YS Mineur","year":"2006","unstructured":"Mineur YS, Belzung C, Crusio WE. Effects of unpredictable chronic mild stress on anxiety and depression-like behavior in mice. Behav Brain Res. 2006;175:43\u201350.","journal-title":"Behav Brain Res"},{"key":"1360_CR103","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.bbr.2015.06.011","volume":"294","author":"E Aarts","year":"2015","unstructured":"Aarts E, et al. The light spot test: Measuring anxiety in mice in an automated home-cage environment. Behav Brain Res. 2015;294:123\u201330.","journal-title":"Behav Brain Res"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-022-01360-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-022-01360-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-022-01360-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T18:33:39Z","timestamp":1727375619000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-022-01360-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,14]]},"references-count":103,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["1360"],"URL":"https:\/\/doi.org\/10.1038\/s41386-022-01360-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.03.22.436517","asserted-by":"object"}]},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,14]]},"assertion":[{"value":"23 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}